Severe
![blank](https://remapcap.co.uk/wp-content/plugins/wp-fastest-cache-premium/pro/images/blank.gif)
Severe disease state is defined as patients who receive organ failure support in an ICU.
Moderate disease state is defined as:
ANTIBIOTICS | NON-PANDEMIC CAP | PANDEMIC |
---|---|---|
A.1 – Ceftriaxone + Macrolide | ![]() ![]() | ![]() ![]() |
A.2 – Moxifloxacin or Levofloxacin | ![]() ![]() | ![]() ![]() |
A.3 – Piperacillin‐Tazobactam + Macrolide | ![]() ![]() | ![]() ![]() |
A.4 – Amoxicillin‐Clavulanate + Macrolide | ![]() ![]() | ![]() ![]() |
Macrolide Duration | NON-PANDEMIC CAP | PANDEMIC |
---|---|---|
M.1 – Standard course macrolide | ![]() ![]() | ![]() ![]() |
M.2 – Extended course macrolide | ![]() ![]() | ![]() ![]() |
Corticosteroid | NON-PANDEMIC CAP / FLU | PANDEMIC |
---|---|---|
C.1 – No corticosteroid | ![]() ![]() | ![]() ![]() |
C.3 – Shock‐dependent hydrocortisone | ![]() ![]() | ![]() ![]() |
C.4 – Fixed‐course dexamethasone | ![]() ![]() | ![]() ![]() |
Influenza Antiviral | NON-PANDEMIC CAP / FLU | PANDEMIC |
---|---|---|
I.1 – No antiviral for influenza | ![]() ![]() | ![]() ![]() |
I.2 – Oseltamivir 5 days | ![]() ![]() | ![]() ![]() |
I.3 – Oseltamivir 10 days | ![]() ![]() | ![]() ![]() |
I.4 – Baloxavir on days 1 and 4 * | ![]() ![]() | ![]() ![]() |
I.5 – 5 days Oseltamivir + Baloxavir on days 1 & 4 * | ![]() ![]() | ![]() ![]() |
I.6 – 10 days Oseltamivir + Baloxavir on days 1 & 4 * | ![]() ![]() | ![]() ![]() |
Immunoglobulin | NON-PANDEMIC CAP | PANDEMIC |
---|---|---|
P.1 – No immunoglobulin for COVID‐19 | ![]() ![]() | ![]() ![]() |
P.2 – High‐titer convalescent plasma | ![]() ![]() | ![]() ![]() |
Immune Modulation | NON-PANDEMIC CAP / FLU | PANDEMIC |
---|---|---|
N.1 – No immune modulation | ![]() ![]() | ![]() ![]() |
N.2 – Tocilizumab | ![]() ![]() | ![]() ![]() |
N.3 – Baricitinib | ![]() ![]() | ![]() ![]() |